The content on this site is intended for healthcare professionals only
Prof Monica Morrow speaks to ecancer in an online interview for the virtual BGICC 2021 meeting about the use of neo-adjuvant chemotherapy to downstage the axilla of women with breast cancer.
She explains that oncology has reached a time where axillary dissection can no longer ben considered the standard of care for the majority of women with breast cancer and discusses recent trials into alternatives.
Prof Morrow concludes that management of the axilla has become increasingly complex and requires a multi-disciplinary approach.
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
Supporting breast cancer patients in Vietnam
The advantages of IORT for early breast cancer treatment
Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC
Neo-adjuvant therapy for different cancers in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
The role of lymph nodes in stage 3 lung cancer
The role of multidisciplinary tumour board in managing stage 3 lung cancer
Cancer pain management
